JP Morgan Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $176
Neurocrine Biosciences, Inc. +3.55%
Neurocrine Biosciences, Inc. NBIX | 130.81 | +3.55% |
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:
NBIX) with a Overweight and lowers the price target from $177 to $176.
